SmithKline Beecham rotavirus vaccine
Executive Summary
Phase II trial for rotavirus vaccine will be delayed until SmithKline gains a better understanding of the adverse event risks in light of Wyeth-Lederle's withdrawal of RotaShield following reports of intussusception, the company said. Merck reports its rotavirus vaccine program will remain unchanged. Wyeth-Lederle said it is planning to pursue a new rotavirus vaccine formulation